It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EBS’s FA Score shows that 1 FA rating(s) are green whileSUPN’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EBS’s TA Score shows that 7 TA indicator(s) are bullish while SUPN’s TA Score has 6 bullish TA indicator(s).
EBS (@Pharmaceuticals: Other) experienced а -5.01% price change this week, while SUPN (@Pharmaceuticals: Other) price change was +1.46% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +8.21%. For the same industry, the average monthly price growth was +10.22%, and the average quarterly price growth was -2.43%.
EBS is expected to report earnings on Feb 20, 2025.
SUPN is expected to report earnings on Mar 04, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
EBS | SUPN | EBS / SUPN | |
Capitalization | 120M | 1.84B | 7% |
EBITDA | -518.2M | 90M | -576% |
Gain YTD | 302.917 | 18.037 | 1,679% |
P/E Ratio | 17.73 | 1677.00 | 1% |
Revenue | 1.02B | 608M | 168% |
Total Cash | 112M | 255M | 44% |
Total Debt | 860M | 41.5M | 2,072% |
EBS | SUPN | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 80 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 95 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 63 | |
SMR RATING 1..100 | 98 | 89 | |
PRICE GROWTH RATING 1..100 | 34 | 42 | |
P/E GROWTH RATING 1..100 | 16 | 1 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EBS's Valuation (65) in the Biotechnology industry is in the same range as SUPN (95) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to SUPN’s over the last 12 months.
SUPN's Profit vs Risk Rating (63) in the Pharmaceuticals Other industry is somewhat better than the same rating for EBS (100) in the Biotechnology industry. This means that SUPN’s stock grew somewhat faster than EBS’s over the last 12 months.
SUPN's SMR Rating (89) in the Pharmaceuticals Other industry is in the same range as EBS (98) in the Biotechnology industry. This means that SUPN’s stock grew similarly to EBS’s over the last 12 months.
EBS's Price Growth Rating (34) in the Biotechnology industry is in the same range as SUPN (42) in the Pharmaceuticals Other industry. This means that EBS’s stock grew similarly to SUPN’s over the last 12 months.
SUPN's P/E Growth Rating (1) in the Pharmaceuticals Other industry is in the same range as EBS (16) in the Biotechnology industry. This means that SUPN’s stock grew similarly to EBS’s over the last 12 months.
EBS | SUPN | |
---|---|---|
RSI ODDS (%) | 2 days ago89% | 2 days ago71% |
Stochastic ODDS (%) | 2 days ago78% | 2 days ago70% |
Momentum ODDS (%) | 2 days ago76% | 2 days ago84% |
MACD ODDS (%) | 2 days ago79% | 2 days ago76% |
TrendWeek ODDS (%) | 2 days ago85% | 2 days ago72% |
TrendMonth ODDS (%) | 2 days ago78% | 2 days ago71% |
Advances ODDS (%) | 15 days ago79% | 2 days ago72% |
Declines ODDS (%) | 7 days ago88% | 20 days ago67% |
BollingerBands ODDS (%) | 2 days ago83% | 2 days ago79% |
Aroon ODDS (%) | 2 days ago88% | 2 days ago72% |
A.I.dvisor tells us that EBS and AMRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EBS and AMRX's prices will move in lockstep.
Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
---|---|---|---|---|
EBS | 100% | +8.29% | ||
AMRX - EBS | 31% Poorly correlated | +1.67% | ||
ZOM - EBS | 29% Poorly correlated | +1.82% | ||
ZTS - EBS | 27% Poorly correlated | +1.53% | ||
SNDL - EBS | 27% Poorly correlated | +1.38% | ||
ACET - EBS | 27% Poorly correlated | +2.14% | ||
More |
A.I.dvisor indicates that over the last year, SUPN has been loosely correlated with PETQ. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if SUPN jumps, then PETQ could also see price increases.
Ticker / NAME | Correlation To SUPN | 1D Price Change % | ||
---|---|---|---|---|
SUPN | 100% | +0.68% | ||
PETQ - SUPN | 41% Loosely correlated | N/A | ||
AMPH - SUPN | 34% Loosely correlated | +2.23% | ||
DVAX - SUPN | 31% Poorly correlated | +6.35% | ||
AMRX - SUPN | 29% Poorly correlated | +1.67% | ||
AQST - SUPN | 28% Poorly correlated | N/A | ||
More |